Hemorrhagic strokes account for about 200,000 strokes per year. Of those who survive, about 66 percent suffer some permanent brain damage. Our guest, biophysicist Dr. Annalisa Scimemi, has been studying the receptors in the brain that may contribute to brain damage immediately after hemorrhagic stroke. Alongside host Dr. Brian McDonough, she will discuss how to lessen the effects of brain damage following a stroke.
The Biophysics of Minimizing Brain Damage After Hemorrhagic Stroke
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Hemorrhagic strokes account for about 200,000 strokes per year. Of those who survive, about 66 percent suffer some permanent brain damage. Our guest, biophysicist Dr. Annalisa Scimemi, has been studying the receptors in the brain that may contribute to brain damage immediately after hemorrhagic stroke. Alongside host Dr. Brian McDonough, she will discuss how to lessen the effects of brain damage following a stroke.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Innovations in the Management of Hemolytic Disease of the Fetus and Newborn: The Role of the Neonatal Fc Receptor (FcRn) Pathway
0.25 credits
<p>Innovations in the Management of Hemolytic Disease of the Fetus and Newborn: The Role of the Neonatal Fc Receptor (FcRn) Pathway</p>
MinuteCE®
I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis
1.00 credits
<p>I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis</p>
CME/CE
Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)
0.50 credits
<p>Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 credits
<p>Level Up Your Skills: Tailoring Management of HF</p>
MinuteCE®
Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy
1.25 credits
<p>Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy</p>
CME/CE
Impact of Barostim on Heart Failure Hospitalization
<p>Impact of Barostim on Heart Failure Hospitalization</p>
NeuroFrontiers
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
<p>Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?